학술논문
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Document Type
Article
Author
Santoni, M.; Battelli, N.; Myint, Z.W.; Büttner, T.; Takeshita, H.; Okada, Y.; Lam, E.T.; Gilbert, D.; Küronya, Z.; Tural, D.; Pichler, R.; Grande, E.; Zabalza, I.O.; Crabb, S.J.; Kemp, R.; Massari, F.; Scagliarini, S.; Iacovelli, R.; Vau, N.; Basso, U.; Maruzzo, M.; Molina-Cerrillo, J.; Galli, L.; Bamias, A.; De Giorgi, U.; Zucali, P.A.; Rizzo, M.; Porta, C.; Seront, E.; Popovic, L.; Caffo, O.; Buti, S.; Kanesvaran, R.; Kopecky, J.; Kucharz, J.; Zeppellini, A.; Fiala, O.; Landmesser, J.; Ansari, J.; Giannatempo, P.; Rizzo, A.; Monteiro, F.S.M.; Calabrò, F.
Source
In: Cancer Immunology, Immunotherapy . (Cancer Immunology, Immunotherapy, September 2023, 72(9):2961-2970)
Subject
Language
English
ISSN
14320851
03407004
03407004